On the stock market since 2018, it operates in the world of health and science. It has 3,595 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Revenue is spread across several lines; no single product carries the company.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 54 buys and 51 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $65.01 — 1,292% above today’s price.
A loss of $122.6M against $915.5M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.9 years. After that, the company needs to find new money.
On our five-subject report card, TLRY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TLRY has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.